Topics

Takeda Pharmaceutical Company Ltd. Company Profile

04:11 EST 27th January 2020 | BioPortfolio


News Articles [821 Associated News Articles listed on BioPortfolio]

DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year

DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Quarter Results/Change in Forecast Takeda Pharmaceutical Company Limited: Takeda Reports Strong First Quarter FY2019 Results and R...

Takeda In-Licenses Investigational Celiac Disease Therapy from COUR Pharmaceuticals

OSAKA, Japan & CHICAGO–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”) today ann...

Chembio Diagnostics and Takeda Pharmaceutical to Collaborate

Chembio Diagnostics (NASDAQ:CEMI) has announced it has entered into an agreement with Shire Human Genetic Therapies, a subsidiary of Takeda Pharmaceutical Company (TYO:4502). As quoted in the press re...

Takeda gibt Leistungskennzahlen für das Geschäftsjahr 2019 bekannt - mit Ausrichtung auf Steigerung des Unternehmenswerts und Schwerpunkt auf eine erfolgreiche Integration

Takeda Pharmaceutical Company Limited (kurz "Takeda") (TOKYO: 4502 NYSE: TAK) gibt bekannt, dass der Takeda-Vorstand die Key Performance Indicators (KPI), die sowohl in die kurz- als auch in die l...

OrbiMed Comments on Takeda Pharmaceutical Company Limited Proxy Ahead of 143rd Ordinary General Meeting of Shareholders 2019

OrbiMed Advisors LLC (“OrbiMed”) has evaluated the proxy voting recommendations from both Institutional Shareholder Services Inc. (“ISS”) and the management of Takeda Phar...

Chembio Diagnostics and Takeda Pharmaceutical Company Collaborate for Development of Point-of-Care Diagnostic Test

MEDFORD, N.Y., July 18, 2019 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care (POC) diagnostics company focused on infectious diseases, today announced that i...

Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2018

Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) hereby announces that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2019 (the “Annual Re...

Acino to buy Takeda’s select OTC and prescription pharmaceutical assets for $200m

The divestment is part of Takeda’s strategy to focus on core business areas and facilitate rapid deleveraging following its acquisition of Shire. Takeda growth and emerging markets business The pos...

Drugs and Medications [397 Associated Drugs and Medications listed on BioPortfolio]

Nesina [takeda pharmaceuticals america, inc.]

These highlights do not include all the information needed to use NESINA safely and effectively. See full prescribing information for NESINA. NESINA (alogliptin) tablets, for oral use Initial U.S. App...

Chlorure de potassium proamp [laboratoire aguettant]

Potassium Chloride for Injection Concentrate, USP

Oxygen [support medical company]

Oxygen

Oxygen [lowry drug company inc. ]

Oxygen

Oxygen [island equipment company]

Oxygen

PubMed Articles [460 Associated PubMed Articles listed on BioPortfolio]

Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?

Another Stem Cell Company Is Put On Notice.

Company Profiles.

Premedical Student Exposure to Pharmaceutical Marketing: Too Much, Too Soon?

Direct pharmaceutical marketing to physicians by pharmaceutical representatives is effective in changing behavior of health care providers, resulting in less evidence-based prescribing. Although much ...

Company Profile: Aldevron Expands to Facilitate Emerging Therapies.

Clinical Trials [487 Associated Clinical Trials listed on BioPortfolio]

A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules

The purpose of this study is to assess the BA of 30 or 60 milligram (mg) dexlansoprazole capsule manufactured at TOB (Takeda GmbH Plant Oranienburg) to the corresponding 30 or 60 mg dexlan...

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

The purpose of this study is to assess the bioavailability of dexlansoprazole from a 30 milligram (mg) or 60 mg delayed-release capsule manufactured at Takeda GmbH Plant Oranienburg, Germa...

Hereditary Angioedema Kininogen Assay

Hereditary angioedema (HAE) is a rare autosomal dominant genetic disorder characterized by recurrent tissue angioedema episodes, mainly caused by mutations in the SERPING1 gene that encode...

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Dexlansoprazole from Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant...

Companies [3105 Associated Companies listed on BioPortfolio]

Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc.

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to ...

Takeda Pharmaceuticals International, Inc.

Located in Deerfield, Illinois, Takeda Pharmaceuticals International, Inc. is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, an industry leader and the larges...

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to ...

Takeda San Francisco, Inc.

Takeda San Francisco, Inc. (TSF), established in November 2007 as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, is Takeda's Biologics Center of Excellence and Antib...

Envoy Therapeutics Inc. and Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global lea...

More Information about "Takeda Pharmaceutical Company Ltd." on BioPortfolio

We have published hundreds of Takeda Pharmaceutical Company Ltd. news stories on BioPortfolio along with dozens of Takeda Pharmaceutical Company Ltd. Clinical Trials and PubMed Articles about Takeda Pharmaceutical Company Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Takeda Pharmaceutical Company Ltd. Companies in our database. You can also find out about relevant Takeda Pharmaceutical Company Ltd. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record